Plain-English translation of NCT07365241 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study compares a new investigational medication called with standard chemotherapy drugs (, , or ) for people with small cell lung cancer that has returned or stopped responding to earlier treatments. About 531 adults will participate across 175 hospitals and clinics worldwide. The trial will track how well the medication works and what side effects occur over approximately 4 years.
Small cell lung cancer is aggressive and spreads quickly, and current standard treatments have limited effectiveness once the cancer returns or becomes resistant. Researchers are testing whether this new treatment approach might help patients live longer and improve their quality of life.
You likely qualify if…
You likely don't qualify if…
You will receive either the new investigational medication or one of the standard chemotherapy drugs through an IV infusion. You will attend regular clinic or hospital visits for medical check-ups, blood tests, scans, and questionnaires to monitor how you are responding to treatment and any side effects. The study lasts about 4 years, though your treatment schedule may vary depending on which arm you are assigned to. Be prepared for more frequent hospital visits and tests than you might normally have with standard care alone.
AI-generated summary from trial data · Sep 19, 2026 · Not medical advice
United States